The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients
Open accessAbstract
Oncolytic adenoviruses and certain chemotherapeutics can induce autophagy and immunogenic cancer cell death. We hypothesized that the combination of oncolytic adenovirus with low-dose temozolomide (TMZ) is safe, effective, and capable of inducing antitumor immune responses. Metronomic low-dose cyclophosphamide (CP) was added to selectively reduce regulatory T-cells. Preclinically, combination therapy inhibited tumor growth, increased autophagy, and triggered immunogenic cell death as indicated by elevated calreticulin, adenosine triphosphate (ATP) release, and nuclear protein high-mobility group box-1 (HMGB1) secretion. A total of 41 combination treatments given to 17 chemotherapy-refractory cancer patients were well tolerated. We observed anti- and proinflammatory cytokine release, evidence of virus replication, and induction of neutralizing antibodies. Tumor cells showed increased autophagy post-treatment. Release of HMGB1 into serum--a possible indicator of immune response--increased in 60% of treatments, and seemed to correlate with tumor-specific T-cell responses, observed in 10/15 cases overall (P = 0.0833). Evidence of antitumor efficacy was seen in 67% of evaluable treatments with a trend for increased survival over matched controls treated with virus only. In summary, the combination of oncolytic adenovirus with low-dose TMZ and metronomic CP increased tumor cell autophagy, elicited antitumor immune responses, and showed promising safety and efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221
Immunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176
High‐mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity
Bianchi, M. E., & Manfredi, A. A. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00574.x · Cited by 600
Cited by
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Self-citationConsensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Self-citationAdenovirus vectors for gene therapy, vaccination and cancer gene therapy
Wold, W., & Toth, K. (2014) · Current Gene Therapy · doi:10.2174/1566523213666131125095046 · Cited by 555
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
Oncolytic Viruses and Their Application to Cancer Immunotherapy
Chiocca, E. A., & Rabkin, S. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0015 · Cited by 408
Combinatorial Strategies for the Induction of Immunogenic Cell Death
Bezu, L., Gomes-de-Silva, L. C., Dewitte, H., Breckpot, K., Fucikova, J., Spisek, R., Galluzzi, L., Kepp, O., & Kroemer, G. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00187 · Cited by 390
Oncolytic viruses for cancer immunotherapy
Hemminki, O., dos Santos, J. M., & Hemminki, A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00922-1 · Cited by 351
Self-citationA Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy
Mu, W., Chu, Q., Liu, Y., & Zhang, N. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00482-6 · Cited by 328
Oncolytic viruses as therapeutic cancer vaccines
Bartlett, D. L., Liu, Z., Sathaiah, M., Ravindranathan, R., Guo, Z., He, Y., & Guo, Z. S. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-103 · Cited by 324
Metronomics: towards personalized chemotherapy?
André, N., Carré, M., & Pasquier, E. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.89 · Cited by 320
Targeting autophagy to sensitive glioma to temozolomide treatment
Yan, Y., Xu, Z., Dai, S., Qian, L., Sun, L., & Gong, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0303-5 · Cited by 299
Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity
Guo, Z. S., Liu, Z., & Bartlett, D. L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00074 · Cited by 284
Zhang, M., Liu, C., Tu, J., Tang, M., Ashrafizadeh, M., Nabavi, N., Sethi, G., Zhao, P., & Liu, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02305-x · Cited by 259
Trial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Ki67 targeted strategies for cancer therapy
Yang, C., Zhang, J., Ding, M., Xu, K., Li, L., Mao, L., & Zheng, J. (2018) · Clinical and Translational Oncology · doi:10.1007/s12094-017-1774-3 · Cited by 254
Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer
Fucikova, J., Moserova, I., Urbanova, L., Bezu, L., Kepp, O., Cremer, I., Salek, C., Strnad, P., Kroemer, G., Galluzzi, L., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00402 · Cited by 159
(2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2165 · Cited by 127
Adenoviral vector-based strategies against infectious disease and cancer
Zhang, C., & Zhou, D. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1165908 · Cited by 110
“127 In a E. G7 tumor-xenograft mouse model, Ad-REIC induced tumorassociated antigen specific cytotoxic T-lymphocytes, and the secreted REIC protein in the tumor generated a proper microenvironment for inducing of activated dendritic cells, resulting in decreased tumor size in the tumor-bearing mice receiving the Ad-RE…”
Adenoviruses as gene/vaccine delivery vectors: Promises and pitfalls
Appaiahgari, M. B., & Vrati, S. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.993374 · Cited by 110
Metadata
- Authors
- Liikanen, I., Ahtiainen, L., Hirvinen, M. L., Bramante, S., Cerullo, V., Nokisalmi, P., Hemminki, O., Diaconu, I., Pesonen, S., Koski, A., Kangasniemi, L., Pesonen, S. K., Oksanen, M., Laasonen, L., Partanen, K., Joensuu, T., Zhao, F., Kanerva, A., & Hemminki, A.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 21
- Issue
- 6
- Pages
- 1212-1223
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2117890938
- Cited by
- 165
- References
- 4
- FWCI
- 12.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.